EUVIMEDEUVIMED entdecken
Crossref

Inhibiting RhoA Activation Via GDP-State Stabilization to Relieve Heart Failure

Mengzhu Xue, Yingquan Liang, Zhen Yuan iD, Xiangning Liu iD, Longfeng Chang iD, Yongzhi Wang, Peijia Xu, Tingting Zhang, Hewei Jiang, Zijie Zhao, Jingqiu Liu, Shanshan Ruan iD und 22 weitere

Circulation Research · 08.05.2026 · 138 (10)

DOI: 10.1161/circresaha.125.327107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Research, erschienen am 08.05.2026. Verfasst von Mengzhu Xue und 33 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai, China (M.X., Y.L., L.C., Yongzhi Wang, P.X.,…. Hauptthemen laut MEDLINE: Heart Failure, rhoA GTP-Binding Protein, Guanosine Diphosphate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Given the persistently high morbidity and mortality of heart failure (HF), targeting myocardial remodeling, particularly pathological hypertrophy and fibrosis, has become a major therapeutic priority. RhoA (Ras homolog gene family member A), a small GTPase governing cytoskeletal reorganization and cell migration, plays a pivotal role in this process. However, RhoA has long been considered undruggable because of its high-affinity binding to GDP/GTP and the absence of well-defined druggable pockets. METHODS: Structural analyses comparing RhoA-GTP and RhoA-GDP conformations, combined with surface plasmon resonance-based screening, were used to identify a RhoA inhibitor. The underlying mechanism was validated in cultured cells and 3-dimensional myocardial tissue models. Therapeutic efficacy was assessed across multiple species of HF models and supported by multiomics analyses linking RhoA activation to human HF. Key findings were further confirmed by multiplex immunohistochemistry and pulldown assays in human heart specimens. RESULTS: We identified an unrecognized cryptic pocket adjacent to GDP in RhoA. A natural product, AH001, selectively occupied this pocket and interacted with GDP, thereby stabilizing the interaction between RhoA and its endogenous inhibitor, RhoGDIα (Rho GDP-dissociation inhibitor 1). AH001 suppressed downstream signaling by reducing MRTFA (myocardin-related transcription factor A) nuclear translocation and downregulating fibrosis- and hypertrophy-related proteins. Moreover, AH001 disrupted pathological crosstalk between Mrtfa + cardiomyocytes and fibroblasts. Consequently, AH001 markedly attenuated myocardial remodeling in multiple HF animal models, as well as in 3-dimensional myocardial tissue models. CONCLUSIONS: These findings establish pharmacological inhibition of RhoA activation as a viable strategy to mitigate myocardial remodeling in HF and provide a conceptual framework for developing reversible inhibitors against previously undruggable small GTPases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailurerhoA GTP-Binding ProteinGuanosine DiphosphateAnimalsHumansMalerho Guanine Nucleotide Dissociation Inhibitor alphaMiceMyocytes, CardiacRatsVentricular RemodelingEnzyme Activation

Stichwörter der Autor:innen

drug therapyfibrosisheart failurehypertrophymultiomics

Substanzen

rhoA GTP-Binding ProteinGuanosine DiphosphateRHOA protein, humanrho Guanine Nucleotide Dissociation Inhibitor alpha

Autor:innen und Institutionen

  • Innovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai, China (M.X., Y.L., L.C., Yongzhi Wang, P.X., T.Z., H.L.).
  • Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, China (Z.Y., L.C., Yongzhi Wang, S.R., T.Y., X.P., W.M., Jiawen Wang, Zhenjiang Zhao, R.W., L.Z., J.Z., H.L.…
  • Modern Research Center for Traditional Chinese Medicine, Key Laboratory of TCM Syndrome and Formula, Ministry of Education, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, China (X. Liu,…
  • Lingang Laboratory, Shanghai, China (H.J.).
  • State Key Laboratory of Natural and Biomimetic Drugs, Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing, China (Zijie Zhao, Jing Wang).
  • Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (J.L., C. Luo).

ORCID-Profile: Zhen Yuan, Xiangning Liu, Longfeng Chang, Shanshan Ruan, Xiaoqian Sun, Huijuan Wang, Yao Zu, Shengce Tao, Jing Wang, Yajun Duan, Lili Zhu, Jian Zhang, Yong Wang, Honglin Li

Zitieren

APA

Xue, M., Liang, Y., Yuan, Z., Liu, X., Chang, L., Wang, Y., Xu, P., Zhang, T., Jiang, H., Zhao, Z., Liu, J., Ruan, S., Ye, T., Pang, X., Mei, W., Wang, J., Sun, X., Wang, H., Cui, J., …, & Li, H. (2026). Inhibiting RhoA Activation Via GDP-State Stabilization to Relieve Heart Failure. Circulation Research, 138(10). https://doi.org/10.1161/circresaha.125.327107

Vancouver

Xue M, Liang Y, Yuan Z, Liu X, Chang L, Wang Y, et al. Inhibiting RhoA Activation Via GDP-State Stabilization to Relieve Heart Failure. Circulation Research. 2026;138(10). doi:10.1161/circresaha.125.327107

BibTeX
@article{Xue2026,
  author = {Xue, Mengzhu and Liang, Yingquan and Yuan, Zhen and Liu, Xiangning and Chang, Longfeng and Wang, Yongzhi and Xu, Peijia and Zhang, Tingting and Jiang, Hewei and Zhao, Zijie and Liu, Jingqiu and Ruan, Shanshan and Ye, Tianyu and Pang, Xuelian and Mei, Wenyi and Wang, Jiawen and Sun, Xiaoqian and Wang, Huijuan and Cui, Jian and Zu, Yao and Lin, Xudong and Zhao, Zhenjiang and Wang, Rui and Huang, Hong and Luo, Cheng and Tao, Shengce and Wang, Jing and Duan, Yajun and Zhu, Lili and Tang, Huifang and Zhang, Jian and Wang, Yong and Li, Chun and Li, Honglin},
  title = {Inhibiting RhoA Activation Via GDP-State Stabilization to Relieve Heart Failure},
  journal = {Circulation Research},
  year = {2026},
  volume = {138},
  number = {10},
  doi = {10.1161/circresaha.125.327107}
}
Kostenlos starten →